HRHani M. Rayess

Hani M. Rayess

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hani M. Rayess has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Amar Gupta

    Department of Otolaryngology - Head and Neck Surgery, Wayne State University School of Medicine, Detroit, MI, USA

    2 shared publications
  • Giancarlo F. Zuliani

    Department of Otolaryngology-Head and Neck Surgery, Wayne State University School of Medicine, Detroit, Michigan

    2 shared publications
  • Michael A. Carron

    Department of Otolaryngology - Head and Neck Surgery, Wayne State University School of Medicine, Detroit, MI, USA; Division of Facial Plastics and Reconstructive Surgery, Department of Otolaryngology - Head and Neck Surgery, Wayne State University School of Medicine, USA

    2 shared publications
  • Peter F. Svider

    Department of Otolaryngology-Head and Neck Surgery, Wayne State University School of Medicine, Detroit, Michigan

    2 shared publications
  • S. Naweed Raza

    Department of Otolaryngology - Head and Neck Surgery, Wayne State University School of Medicine, Detroit, MI, USA; Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA

    2 shared publications
  • Andrew M. Fribley

    Department of Otolaryngology - Head and Neck Surgery, Wayne State University School of Medicine, Detroit, MI, USA; Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA; Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Detroit, MI, USA; Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA

    1 shared publication

Latest Publications

  • Top Cited Papers

    A Cross-sectional Analysis of Adverse Events and Litigation for Injectable Fillers

    by Hani M. Rayess, Peter F. Svider, Curtis Hanba, Vivek Sagar Patel, Louis M. DeJoseph, Michael Carron, Giancarlo F. Zuliani

    Importance: Injectable fillers are increasing in popularity as a noninvasive option to address concerns related to facial aging and volume loss. To our knowledge, there have been no large-scale analyses of adverse events and associated litigation related to filler injections. Objectives: To determine risks of injectable fillers and analyze factors raised in litigation related to injectable fillers. Design, Setting, and Participants: In this cross-sectional review, the US Food and Drug Administration’s (FDA) manufacturer and user facility device experience (MAUDE) database was evaluated for complications from the use of the following fillers: Juvederm, Restylane, Belotero, Sculptra, Radiesse, Artefill, Bellafill, and Juvederm Voluma from 2014 to 2016. The Westlaw Next database was used to identify jury verdicts. Main Outcomes and Measures: Complications were organized by type of filler used, location of injection, and severity. Intra-arterial injections without sequelae and those resulting in blindness or necrosis were considered severe complications. Factors raised during the litigation process were also analyzed. Results: Of 1748 adverse events analyzed, most cases stemmed from cheek (751 [43.0%]) or lip (524 [30.0%]) injection. Commonly reported adverse events reported included swelling (755 [43.2%]) and infection (725 [41.5%]). Among FDA-reported complications, blindness was significantly associated with dorsal nasal injections ( P < .001). Vascular compromise with and without sequela of dermal necrosis and blindness were significantly associated with Radiesse injections P < .001. Of the 9 malpractice cases identified, two-thirds involved allegations of inadequate informed consent, and the median award in cases resolved with payment was $262 000. Conclusions and Relevance: Although specific complication profiles vary by material and injection site, common adverse events associated with injectable fillers include swelling and infection. More serious events include vascular compromise, resulting in necrosis and blindness; these events are also raised in cases involving litigation. This analysis illustrates the importance of outlining these risks in a comprehensive preoperative informed consent process. Level of Evidence: NA .


  • Oropharyngeal lymphoma: A US population based analysis

    by Hani M. Rayess, Michael Nissan, Amar Gupta, Michael A. Carron, S. Naweed Raza, Andrew M. Fribley


  • A critical analysis of melanoma malpractice litigation: Should we biopsy everything?

    by Hani M. Rayess, Amar Gupta, Peter F. Svider, S. Naweed Raza, Mahdi Shkoukani, Giancarlo F. Zuliani, Michael A. Carron

    Objectives/Hypothesis The aim of this study was to evaluate factors raised in malpractice litigation related to the diagnosis and management of melanoma and to further assess issues impacting outcome. Study Design Retrospective chart review. Methods The Westlaw legal database was searched for malpractice litigation resolved over the last 20 years relating to melanoma. Cases were evaluated for allegations, defendant specialty, outcome, and other issues raised. Results Of the 80 cases evaluated, 49% were resolved in the defendants' favor. In greater than 80% of cases, there was alleged misdiagnosis. In 35% of cases, the patient had expired secondary to melanoma at the time of litigation. There was no statistical difference in payments upon comparison of cases with and without mortality. A greater proportion of cases with dermatologists and pathologists as defendants involved alleged misdiagnosis. The most common locations for melanoma were the extremities and the head-and-neck region, at 32.5% and 22.5%, respectively. Location did not significantly impact the outcome of cases. Conclusion Malpractice litigation relating to melanoma involves numerous physicians, including dermatologists, pathologists, and otolaryngologists. Alleged misdiagnosis of a pigmented lesion was the most common cause of litigation and involved physicians from numerous specialties. Patients who were misdiagnosed had a significantly higher likelihood of having active disease at the time of litigation. Ultimately improved methods of detecting concerning pigmented lesions need to be developed. Factors such as death and poor cosmetic outcome did not significantly impact litigation outcome. Level of Evidence NA Laryngoscope, 127:134–139, 2017